Original Article

Does apolipoprotein A-II polymorphism interact with the association of obesity and serum inflammatory biomarkers in type 2 diabetes patients?


Background: The objective was to investigate the relationship between serum interleukin-18 (IL-18), pentraxin 3 (PTX3), and high-sensitivity C-reactive protein (hs-CRP) levels with body mass index (BMI) and abdominal obesity and also the interaction between genetic variants of apolipoprotein A-II (Apo A-II) and obesity on the levels of these factors in type 2 diabetes patients (T2D).
Methods:  A  comparative  cross-sectional study  was  conducted  in  21  diabetes centers in Tehran. Totally, 180 (35-65 years) T2D patients were divided into two groups of 90 obese (BMI ≥ 30) and 90 non-obese (BMI < 30), according to the BMI with equal numbers of each genotype of Apo A-II: 30 TT, 30 CC, and 30 TC. Serum IL-18, PTX3, and hs-CRP concentrations were compared between two obese  and  non-obese  groups  and  between  subjects  with  and  without  central obesity. To investigate the interaction of Apo A-II genetic variants and BMI with inflammatory factors, general linear model was used.
Results: After adjusting data with confounding factors, the mean of serum PTX3 was significantly lower (p < 0.050) in the obese diabetes than non-obese diabetes subjects. Moreover, obese diabetes had higher serum hs-CRP level that on obese subjects (p < 0.010). No significant interaction between Apo A-II 265 T > C polymorphism and BMI on inflammatory biomarkers was observed.
Conclusion: There was a significant difference in inflammatory markers (PTX3 and hs-CRP concentration) between obese and non-obese diabetes. In addition, there was no interaction of Apo A-II 265 T > C genotypes and BMI on inflammatory markers. Weight control may be recommended to modulate inflammation and its complications in obese patients.

Esteghamati A, Ashraf H, Khalilzadeh O, Rashidi A, Mohammad K, Asgari F, et al. Trends of diabetes according to body mass index levels in Iran: results of the national Surv ys of Risk Factors of Non-Communicable Diseases (1999-2007). Diabet Med. 2010; 27(11): 1233-40.

International Diabetes Federation. IDF Diabetes Atlas. 5th ed. Brussels, Belgium: International Diabetes Federation, Executive Office; 2011.

Saadat N, Emami H, Salehi P, Azizi F.Comparison of ADA and WHO criteria in detecting glucose disorders in a population-based study: Tehran Lipid and Glucose Study. Iran J Endocrinol Metab. 2002; 4(1): 1-8. [In Persian].

Ramezani A, Tahbaz F, Rasouli S, Nistani T, Rashidkhani B, Hedayati M. The Effects of Fortified Carrot Juice with Beta Carotene on Insulin Resistance Indices in Patients with Type II Diabetes. J Mazandaran Univ Med Sci. 2010;20(78): 59-68. [In Persian].

Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006; 83(2): 461S-5S.

Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm. 2010; 2010.

Hansen D, Dendale P, Beelen M, Jonkers RA, Mullens A, Corluy L, et al. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol. 2010; 109(3): 397-404.

Salek Zamani S, Neyestani T, Kalayi A, Alavimajd H, Hoshyarrad A, Nikooyeh B, et al. Determinants of inflammation and systolic blood presure in women with central obesity: a cross- sectional study. Iran J Nutr Sci Food Technol. 2011; 6(2): 1-10. [In Persian].

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3): 499-511.

Ridker PM, Hennekens CH, Buring JE, Rifai N.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342(12):836-43.

Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010; 1212: E1-E19.

Fullerton SM, Clark AG, Weiss KM, Taylor SL, Stengard JH, Salomaa V, et al. Sequence polymorphism at the human apolipoprotein AII gene (APOA2): unexpected deficit of variation in an African-American sample. Hum Genet. 2002;111(1): 75-87.

Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res. 2001; 42(11):1727-39.

van't Hooft FM, Ruotolo G, Boquist S, de Faire U, Eggertsen G, Hamsten A. Human evidence that the apolipoprotein a-II gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins. Circulation. 2001;104(11): 1223-8.

Corella D, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, Hixson JE, et al. The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. Clin Chem. 2007; 53(6):1144-52.

Corella D, Peloso G, Arnett DK, Demissie S, Cupples LA, Tucker K, et al. APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations. Arch Intern Med. 2009; 169(20): 1897-906.

Smith CE, Ordovas JM, Sanchez-Moreno C, Lee YC, Garaulet M. Apolipoprotein A-II polymorphism: relationships to behavioural and hormonal mediators of obesity. Int J Obes (Lond).2012; 36(1): 130-6.

Lara-Castro C, Hunter GR, Lovejoy JC, Gower BA, Fernandez JR. Apolipoprotein A-II polymorphism and visceral adiposity in African- American and white women. Obes Res. 2005;13(3): 507-12.

Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J.2006; 82(966): 280-4.

Bjorbaek C, Kahn BB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res. 2004; 59: 305-31.

Noorshahi N. Investigating frequency of Apo A- II genotypes and interaction of these genotypes and consumption of saturated fatty acids with lipid profile, ghrelin and leptin levels in type 2 diabetic patients [MSc Thesis]. Tehran, Iran: School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences; 2012. [In Persian].

Mirmiran P, Esfahani FH, Mehrabi Y, Hedayati M, Azizi F. Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. Public Health Nutr. 2010; 13(5): 654-62.

Aadahl M, Jorgensen T. Validation of a new self- report instrument for measuring physical activity. Med Sci Sports Exerc. 2003; 35(7): 1196-202.

Mahan LK, Escott-Stump S, Raymond JL.Krause's food and the nutrition care process. Philadelphia, PA: Elsevier Health Sciences; 2012.

Centers for Disease Control and Prevention.Overweight and Obesity. Version current 2009. Internet: http://www.cdc.gov/nchs/fastats/obesity-overweight.htm (accessed 14 January 2015)

Sikaris KA. The clinical biochemistry of obesity.Clin Biochem Rev. 2004; 25(3): 165-81.

Alvandi E, Koohdani F. Zip nucleic acid: a new reliable method to increase the melting temperature of real-time PCR probes. J Diabetes Metab Disord. 2014; 13(1): 26.

Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord. 2001; 25(9): 1327-31.

Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schonbeck U, Khera A, et al. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol. 2007;27(9): 2043-9.

Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A, et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis. 2009; 202(2): 455-60.

Ogawa T, Kawano Y, Imamura T, Kawakita K, Sagara M, Matsuo T, et al. Reciprocal contribution of pentraxin 3 and C-reactive protein to obesity and metabolic syndrome. Obesity (Silver Spring). 2010; 18(9): 1871-4.

Bahceci M, Gokalp D, Bahceci S, Tuzcu A, Atmaca S, Arikan S. The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C- reactive protein levels. Is adipocyte size associated with inflammation in adults? J Endocrinol Invest. 2007; 30(3): 210-4.

Hasegawa G, Ohta M, Ichida Y, Obayashi H, Shigeta M, Yamasaki M, et al. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetol. 2005; 42(2): 104-9.

Carroll JF, Fulda KG, Chiapa AL, Rodriquez M, Phelps DR, Cardarelli KM, et al. Impact of race/ethnicity on the relationship between visceral fat and inflammatory biomarkers. Obesity (Silver Spring). 2009; 17(7): 1420-7.

Lee S, Jensen MD. Adipogenic risk factor differences between Korean and white adults-- potential role of plasma free fatty acid and adiponectin. Metabolism. 2009; 58(2): 270-4.

Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat,leptin, and insulin resistance in Asian Indian men.J Clin Endocrinol Metab. 1999; 84(1): 137-44.

Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, Esquivel-Soto J, Morales-Gonzalez A, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci. 2011;12(5): 3117-32.

Zarghami N, Mohamadzadeh G, Zahedi Asl S, Hosseinpanah F. Changes of Serum Leptin Levels in Healthy Women with Different Grades of Obesity and its Correlation with Hormonal and Anthropometric Factors. Iran J Endocrinol Metab.2008; 10(3): 227-34. [In Persian].

Bravo PE, Morse S, Borne DM, Aguilar EA, Reisin E. Leptin and hypertension in obesity. Vasc Health Risk Manag. 2006; 2(2): 163-9.

Esposito K, Nappo F, Giugliano F, Di PC, Ciotola M, Barbieri M, et al. Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr.2003; 78(6): 1135-40.

Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002; 106(16): 2067-72.

Wang Y, Niimi M, Nishijima K, Waqar AB, Yu Y, Koike T, et al. Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits. Arterioscler Thromb Vasc Biol. 2013; 33(2): 224-31.

IssueVol 1, No 2 (spring 2015) QRcode
SectionOriginal Article(s)
Inflammation Obesity Apolipoprotein A-II Type 2 diabetes Gene Polymorphism

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Keramat L, Eshraghian M, Djalali M, Sotoudeh G, Sadrzadeh-Yeganeh H, Koohdani F. Does apolipoprotein A-II polymorphism interact with the association of obesity and serum inflammatory biomarkers in type 2 diabetes patients?. J Nutr Sci & Diet. 1(2):107-113.